## 3 Results and Discussion
### State of the Art Regarding This Implant
\begin{table}
\begin{tabular}{c c c c c c c c c} \hline \hline \multicolumn{1}{c}{\multirow{2}{*}{**Reference**}} & \multicolumn{4}{c}{**Current Clinical Evidence of Prama Implants Published Up to June 2024**} \\ \hline \multirow{2}{*}{**Reference**} & **Type of the Study** & \multirow{2}{*}{**N Implants**} & **Surgery and Insertion** & **Implant Type** & **Follow-Up** & **Prosthetic Approach** & **Survival** & **Funding** \\ \hline [PERSON] et al., & & & Flap & Prama RF & & & & \\
2021 [30] & Prospective & 120 (60/60) & \begin{tabular}{c} supratextual \\ \end{tabular} & \
\begin{tabular}{c} Prama RF \\ \end{tabular} & 1 year & Screw retained & 100\% &
\begin{tabular}{c} No external \\ funding \\ \end{tabular} \\ \hline [PERSON] et al., & & & Flap & & & & & \\
2019 [28] & Pilot study & 32 & \begin{tabular}{c} supratextual \\ \end{tabular} & \begin{tabular}{c} supratextual \\ \end{tabular} & \
\begin{tabular}{c} Prama \\ \end{tabular} & 13 months & Cemented & 100\% &
\begin{tabular}{c} No external \\ funding \\ \end{tabular} \\ \hline [PERSON] et al., & & & Flap & & & & & \\
[25] & Retrospective & 48 (27/21) & \begin{tabular}{c} Flap \\ \end{tabular} & \
\begin{tabular}{c} Prama \\ \end{tabular} & 5 years & Cemented & 100\% &
\begin{tabular}{c} No external \\ funding \\ \end{tabular} \\ \hline [PERSON] et al., & & & Flap & & & & & \\
[31] & Retrospective & 30 (10/10/10) & \begin{tabular}{c} supratextual \\ \end{tabular} & \
\begin{tabular}{c} Prama, \\ \end{tabular} & 1 year & Screw retained & 100\% &
\begin{tabular}{c} No external \\ funding \\ \end{tabular} \\ \hline [PERSON] et al., & & & Flap & & & & & \\
2022 [27] & Prospective & 30 & \begin{tabular}{c} crestal \\ insertion + \\ \end{tabular} & \
\begin{tabular}{c} Prama \\ \end{tabular} & 1 year & Screw retained & 100\% &
\begin{tabular}{c} No external \\ funding \\ \end{tabular} \\ \hline [PERSON] et al., & & & Flap & & & & & \\
2022 [20] & Ambispective & 32 & \begin{tabular}{c} Bone level \\ \end{tabular} & \begin{tabular}{c} Prama \\ \end{tabular} & 16 months & Screw retained & 100\% & \begin{tabular}{c} No external \\ fundings \\ \end{tabular} \\ \hline [PERSON] et al., & & Randomized & 29 & \begin{tabular}{c} Plam \\ \end{tabular} & \
\begin{tabular}{c} Prama \\ \end{tabular} & 1 year & Cemented & 100\% &
\begin{tabular}{c} Partially \\ supported by \\ Sweden and \\ \end{tabular} \\ \hline [PERSON] et al., & & & Flap & & & & \\
[17] & Prospective & 67 & \begin{tabular}{c} Tlague \\ level/Exposed \\ \end{tabular} & \
\begin{tabular}{c} Prama \\ \end{tabular} & 6 years & Cemented & 100\% &
\begin{tabular}{c} No external \\ fundings \\ \end{tabular} \\ \hline [PERSON] et al., & & & Flap & & & & & \\
[22] & Retrospective & (80/76) & \begin{tabular}{c} Flap \\ Bone level \\ \end{tabular} & \
\begin{tabular}{c} Shelta, Syra \\ Prama \\ \end{tabular} & 2 years & Screw retained & 97.37\% &
\begin{tabular}{c} No external \\ fundings \\ \end{tabular} \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Clinical studies published in the period 2014-2024. When multiple studies by the same research group included the same population sample but with different follow-up durations, only the study with the longest follow-up was considered.